Krystyna O.
- Country
- Poland
- Department
- N/A
Research Overview
- Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial
- Phase 3 Randomized, Placebo‑Controlled Trial Assessing Efficacy and Safety of MET097, a Long‑Acting GLP‑1 Receptor Agonist, in Overweight/Obese Adults with Type 2 Diabetes
- Evaluation of Long-term Effects of Semaglutide Versus Placebo on Diabetic Retinopathy Progression in Type 2 Diabetes Patients
Data & Insights
Has run more than one trial at 105 of 208 partner sites.
Specializations
Diabetes Research
The investigator specializes in studying the relationship between type 2 diabetes and its ocular complications, with particular emphasis on therapeutic interventions using semaglutide.
- Diabetic Retinopathy Management
- Glycemic Control Assessment
- Long-term Treatment Outcomes
Their work examines the effects of diabetes medications on eye health outcomes.
Ophthalmology Focus
Expertise centers on diabetic retinopathy progression and development, utilizing standardized ophthalmic assessment techniques to evaluate disease outcomes.
- Early Worsening Phenomenon
- Retinal Disease Progression
- Vision Protection Strategies
The research encompasses comprehensive evaluation of ocular health in diabetic patients.
Clinical Safety Studies
Conducts post-authorization safety studies in collaboration with regulatory authorities, focusing on long-term medication effects.
- Treatment Safety Assessment
- Standard-of-Care Integration
- Therapeutic Monitoring
Their research contributes to establishing safety profiles of diabetes treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.